Nasopulmonary drug delivery system: Introduction to Nasal and Pulmonary routes of drug delivery, Formulation of Inhalers (dry powder and metered dose), nasal sprays, nebulizers
Eye drops, lotions, ointments and other ophthalmic preparations must meet several requirements to be safely applied to the eyes. They must be sterile, isotonic to tears, and free of particles to avoid irritation. Various formulations exist, including liquids, gels and solids, which are prepared through clarification, sterilization and packaging in sterile containers. Common ingredients include drugs, preservatives, viscosity agents and buffers to maintain the correct pH, tonicity and stability for ocular administration.
In this slide contains introduction, copmpression, consolidation, compaction, heckel plots and equation, interpretation and application.
Presented by: NARAYAN SINGH UDIT (Department of pharmaceutics).
RIPER, anantapur
The document discusses ocular drug delivery systems. It begins with an introduction to ocular drug delivery and the need for such systems given barriers to drug permeation in the eye. It then covers eye anatomy and physiology, classification of various ocular drug delivery systems including conventional and vesicular systems, methods to overcome barriers like penetration enhancers, and ideal characteristics of ocular delivery systems. Evaluation of these systems is also mentioned.
This document summarizes ophthalmic preparations including definitions, commonly used dosage forms, drugs used in the eye, anatomy and physiology of the eye, factors affecting drug absorption in the eye, manufacturing considerations, and classification of ocular drug delivery systems such as topical eye drops, ointments, and inserts. Key points covered include the types of solutions, suspensions, and gel-forming solutions used as topical eye drops, as well as inactive ingredients used to adjust tonicity, pH, provide stability, and impart viscosity.
The document discusses preformulation studies, which involve characterizing the physical and chemical properties of a drug substance before developing a dosage form. The goals are to generate stability-indicating parameters and select an appropriate dosage form. Key topics covered include the physical properties tested (such as solubility, polymorphism, particle size), chemical degradation pathways (such as hydrolysis, oxidation), and how these properties influence dosage form design and drug performance. Understanding a drug's preformulation behavior is critical for developing a safe, effective, and stable drug product.
- The document discusses nonlinear pharmacokinetics where parameters like clearance and volume of distribution change with dose. This occurs when transporters or enzymes involved in absorption, distribution, metabolism and excretion get saturated at high drug concentrations.
- The Michaelis-Menten equation is used to describe saturation kinetics and estimate parameters Km and Vmax. Various methods like Lineweaver-Burk, direct linear and graphical plots are presented to determine these values using in vivo or in vitro concentration and rate data.
- Estimation of Km and Vmax is also described at steady-state concentrations achieved after constant rate infusion or multiple dosing, through plots of steady-state concentration versus dosing rate.
The document provides information on quality control testing for pharmaceutical tablets. It defines quality control as the process of monitoring quality during manufacturing to ensure standards are met. It describes several important quality control tests conducted on tablets, including weight variation, thickness, hardness, friability, disintegration, dissolution, and content uniformity tests. These tests are essential to ensure tablets are safe, effective, and meet specifications for attributes like drug content, stability and patient acceptability. The document provides details on procedures, equipment and acceptance criteria for each quality control test.
Nasopulmonary drug delivery system: Introduction to Nasal and Pulmonary routes of drug delivery, Formulation of Inhalers (dry powder and metered dose), nasal sprays, nebulizers
Eye drops, lotions, ointments and other ophthalmic preparations must meet several requirements to be safely applied to the eyes. They must be sterile, isotonic to tears, and free of particles to avoid irritation. Various formulations exist, including liquids, gels and solids, which are prepared through clarification, sterilization and packaging in sterile containers. Common ingredients include drugs, preservatives, viscosity agents and buffers to maintain the correct pH, tonicity and stability for ocular administration.
In this slide contains introduction, copmpression, consolidation, compaction, heckel plots and equation, interpretation and application.
Presented by: NARAYAN SINGH UDIT (Department of pharmaceutics).
RIPER, anantapur
The document discusses ocular drug delivery systems. It begins with an introduction to ocular drug delivery and the need for such systems given barriers to drug permeation in the eye. It then covers eye anatomy and physiology, classification of various ocular drug delivery systems including conventional and vesicular systems, methods to overcome barriers like penetration enhancers, and ideal characteristics of ocular delivery systems. Evaluation of these systems is also mentioned.
This document summarizes ophthalmic preparations including definitions, commonly used dosage forms, drugs used in the eye, anatomy and physiology of the eye, factors affecting drug absorption in the eye, manufacturing considerations, and classification of ocular drug delivery systems such as topical eye drops, ointments, and inserts. Key points covered include the types of solutions, suspensions, and gel-forming solutions used as topical eye drops, as well as inactive ingredients used to adjust tonicity, pH, provide stability, and impart viscosity.
The document discusses preformulation studies, which involve characterizing the physical and chemical properties of a drug substance before developing a dosage form. The goals are to generate stability-indicating parameters and select an appropriate dosage form. Key topics covered include the physical properties tested (such as solubility, polymorphism, particle size), chemical degradation pathways (such as hydrolysis, oxidation), and how these properties influence dosage form design and drug performance. Understanding a drug's preformulation behavior is critical for developing a safe, effective, and stable drug product.
- The document discusses nonlinear pharmacokinetics where parameters like clearance and volume of distribution change with dose. This occurs when transporters or enzymes involved in absorption, distribution, metabolism and excretion get saturated at high drug concentrations.
- The Michaelis-Menten equation is used to describe saturation kinetics and estimate parameters Km and Vmax. Various methods like Lineweaver-Burk, direct linear and graphical plots are presented to determine these values using in vivo or in vitro concentration and rate data.
- Estimation of Km and Vmax is also described at steady-state concentrations achieved after constant rate infusion or multiple dosing, through plots of steady-state concentration versus dosing rate.
The document provides information on quality control testing for pharmaceutical tablets. It defines quality control as the process of monitoring quality during manufacturing to ensure standards are met. It describes several important quality control tests conducted on tablets, including weight variation, thickness, hardness, friability, disintegration, dissolution, and content uniformity tests. These tests are essential to ensure tablets are safe, effective, and meet specifications for attributes like drug content, stability and patient acceptability. The document provides details on procedures, equipment and acceptance criteria for each quality control test.
The document discusses ocular inserts, which are thin, solid or semi-solid drug-impregnated devices placed in the eye to provide prolonged drug delivery. It defines ocular inserts and describes different types including soluble, insoluble, and erodible inserts. Applications include treatments for glaucoma, infections, and inflammation. Advantages are prolonged contact time and drug release, while disadvantages include potential loss or irritation. The document outlines manufacturing methods and innovations in ocular insert technologies and drug delivery to the eye.
Preformulation studies characterize the physical and chemical properties of drug molecules to develop safe, effective, and stable dosage forms. The goals are to develop formulations that are stable, safe, and effective. Major areas of study include physical characterization of properties like crystallinity and polymorphism, hygroscopicity, particle size, and powder flow. Solubility is analyzed through measurements of ionization, partition coefficient, aqueous solubility, and pH-solubility profiles. Stability is analyzed through studies of photolytic stability, stability to oxidation, and drug-excipient compatibility.
2 Aspects of compatibility tests are:
Identification of compatible excipients for a formulation.
Identification of stable storage conditions
2 Types:
Solid state reactions: much slower and difficult to interpret.
Liquid state reactions: easier to detect
According to Stability Guidelines by FDA following conditions should be evaluated for solutions or suspensions
1. Acidic or alkaline pH.
2. Presence of added substances
3. High oxygen and nitrogen atmospheres.
4. Effect of stress testing conditions.
This document discusses various aspects of drug release and dissolution. It begins by defining the five types of dosage forms that can be characterized by in vitro release, including solid oral dosage forms. It then discusses key concepts like drug products, drug substances, drug release mechanisms for different release types (immediate, delayed, extended), and modified-release dosage forms. The document also provides the definitions and differences between dissolution-controlled systems, diffusion-controlled systems, and combined dissolution-diffusion systems. It introduces mathematical models for drug dissolution like the Noyes-Whitney equation and Hixson-Crowell cube root equation. Finally, it discusses factors that affect drug dissolution and release rates.
Excipients are inactive substances formulated with active pharmaceutical ingredients to create drug products. They serve important purposes like bulking up formulations, ensuring consistent drug release and stability, and determining properties of the final dosage form like tablet size and dissolution rate. Common excipients include diluents, binders, disintegrants, lubricants, and glidants. Diluents increase volume and include substances like lactose, starch and calcium phosphate. Binders promote adhesion while disintegrants facilitate breaking of tablets. Lubricants prevent adhesion during compression and glidants promote powder flow. Proper excipient selection is crucial for an efficacious and robust drug product.
This document provides an overview of inhalation aerosols, including the propellants used, packaging, and filling techniques. It discusses the main components of aerosols like propellants, containers, valves, and actuators. The two main types of propellants are liquefied gas propellants and compressed gas propellants. It also summarizes the advantages and disadvantages of aerosols as well as the pressure filling and cold filling methods used to manufacture pharmaceutical aerosols.
Evaluation of transdermal drug delivery systemSagar Savale
This document discusses the evaluation of transdermal drug delivery systems. Key aspects that are evaluated include physicochemical properties, adhesive properties, in vitro studies, in vivo studies, stability studies, and toxicological studies. These evaluations are important to ensure consistency between batches in terms of quality, performance, reproducibility and stability, and to predict factors that may influence drug delivery.
Gastro retentive drug delivery system (GRDDS)Shweta Nehate
This document discusses gastro-retentive drug delivery systems (GRDDS), which aim to prolong the gastric residence time of drugs and target drug release in the upper gastrointestinal tract. It describes the physiology of the gastrointestinal tract and potential drug candidates for GRDDS. Various approaches for GRDDS are covered, including floating, high density, bioadhesive, swelling, and superporous hydrogel systems. Evaluation parameters, applications, marketed formulations, and conclusions about GRDDS are also summarized.
1. Capsules are solid dosage forms that enclose one or more active ingredients in a soluble gelatin shell for oral administration. Hard capsules use gelatin and contain dry powders, while soft capsules contain oils or liquids dissolved in oils.
2. Capsules are manufactured through rotary die or reciprocating die processes that form, fill, seal and cut the gelatin shells. The gelatin used is type A or B derived from animal collagen.
3. Finished capsules are tested for attributes like size, shape, weight uniformity, content uniformity, and dissolution. Soft gelatin capsules provide benefits like protecting unstable ingredients and increasing bioavailability but have certain material limitations.
Anatomy of eye and adrena, absorption of drug in the eye, classification of ophthalmic
products, safety consideration of ophthalmic products, formulation, vehicles and additives,
manufacturing consideration, environment, manufacturing techniques, quality control of
ophthalmic products, packaging of ophthalmic products.
The phenomenon of complex formation of drug with protein is called as Protein drug binding. The proteins are particularly responsible for such an interaction. A drug can interact with several tissue components.
ALZET osmotic pumps are implantable devices that continuously deliver solutions over a set duration at a constant rate. They offer a simple alternative to repetitive injections by providing around-the-clock exposure to test agents without needing frequent animal handling. ALZET pumps work through osmosis, using no batteries or electronics. They have various sizes to deliver agents from 1 day to 6 weeks at controlled rates. Common applications include delivering drugs, hormones, and other compounds in animal research.
This document provides an overview of microencapsulation techniques with a focus on coacervation phase separation. It defines coacervation as the partial desolvation of a homogeneous polymer solution into a polymer-rich phase and poor polymer phase. The key steps of coacervation formation are the formation of three immiscible chemical phases, deposition of the coating, and rigidization of the coating. Various techniques used for coacervation include changes in temperature, addition of incompatible polymers, addition of non-solvents, addition of salts, and polymer-polymer interactions. Modified coacervation techniques discussed include aqueous phase separation, organic phase separation, solvent evaporation, encapsulation by polyelectrolyte multilayer, hydrogel micro
Polymers Used in Pharmaceutical SciencesOyshe Ahmed
INTRODUCTION
CLASSIFICATION AND CHARACTERISTICS OF POLYMERS
MECHANISM OF DRUG RELEASE FROM POLYMER
BIO DEGRADATION OF POLYMERS
SYNTHESIS OF POLYMERS
POLYMERS USED IN FORMULATION OF DIFFERENT DRUG DELIVERY SYSTEM.
APPLICATION OF POLYMERS
The document discusses thixotropy, which is defined as the reversible transformation of a semi-solid material from a solid state to a liquid state and back again due to applied stress over time. Examples of thixotropic materials include ketchup, paints, and yogurt. A key characteristic of thixotropic materials is their hysteresis loop, which is formed on a rheogram by the upcurve and downcurve of viscosity with increasing and decreasing shear rates. The area of the hysteresis loop can be used to measure the degree of thixotropic breakdown. Thixotropy is a desirable property for liquid pharmaceuticals as it allows the material to have a high consistency at rest but flow easily upon shaking before reg
This document summarizes ocular drug delivery systems. It discusses barriers to drug permeation through the eye such as anatomical barriers like the cornea and physiological barriers like tear turnover. It also discusses strategies to overcome these barriers, including using viscosity enhancers to prolong precorneal residence time, penetration enhancers to increase corneal permeability, and various drug delivery vehicles like ointments, gels, liposomes, nanoparticles, microemulsions, and in-situ forming gels that can enhance ocular absorption and bioavailability. The ideal ocular delivery system maximizes precorneal residence time and drug absorption while minimizing systemic exposure and side effects.
This document discusses drug interactions at plasma and tissue binding sites. It describes the mechanisms of protein drug binding, including reversible and irreversible binding via hydrogen bonds, hydrophobic bonds, ionic bonds, and Vander Waal's forces. It explains how drugs can bind to blood components like plasma proteins, albumin, alpha-1-acid glycoprotein, lipoproteins, globulins, and blood cells. It also discusses how drugs can bind to extravascular tissues in organs like the liver, kidneys, lungs, and muscles. The significance of protein and tissue binding on drug absorption, distribution, elimination, therapy and drug targeting is explained.
The document describes different types of tablets classified by method of administration and mechanism of action. Tablets can be ingested orally and include standard, enteric coated, chewable and effervescent varieties. Others are used in the oral cavity as buccal, sublingual or lozenges. Implantation and vaginal tablets are administered by other routes. Tablet types aim to protect drugs, modify release timing, or produce solutions for various therapeutic effects.
This document compares different methods for comparing dissolution profiles of drug products. It defines dissolution profile comparison and its objectives such as developing bioequivalent products and in vitro-in vivo correlations. Graphical, statistical, model-dependent and model-independent methods are described. The most common model-independent method is the f2 similarity factor test recommended by the FDA, which provides a single value to determine if two dissolution profiles are similar based on the percent dissolved over time. Proper selection of time points and criteria for coefficient of variation are important for f2 testing.
ocular barriers and methods to overcome barriersTarun Gollapudi
This document summarizes barriers to ocular drug delivery and methods to overcome them. The major barriers include ocular surface barriers like the cornea, ocular wall barriers like the sclera, retinal barriers, the vitreous body, lachrymal fluid, and properties of the drug itself like solubility and molecular weight. Methods to enhance delivery include microneedles, ultrasound, iontophoresis, periocular routes, and intravitreal injections. Various ophthalmic formulations are also discussed like eye drops, gels, ointments, and inserts that utilize approaches like prodrugs, penetration enhancers, and nanoparticle carriers to improve ocular bioavailability.
This document discusses ophthalmic products and drug delivery to the eye. It provides information on general requirements for ocular formulations including safety, toxicity, and preservation. It describes the anatomy and physiology of the eye and barriers to drug absorption such as tear drainage and corneal permeability. The document outlines various approaches for ocular drug delivery including in-situ gels, liposomes, nanoparticles, inserts and implants to prolong drug residence in the eye.
The document provides an overview of ophthalmic products and drug delivery systems for the eye. It discusses general requirements for ocular formulations including safety, toxicity, preservation and barriers to drug absorption in the eye. It also describes various conventional and novel ocular drug delivery approaches such as in-situ gels, liposomes, nanoparticles, inserts and implantable systems. The anatomy and physiology of the eye is reviewed along with factors affecting drug availability after ocular administration.
The document discusses ocular inserts, which are thin, solid or semi-solid drug-impregnated devices placed in the eye to provide prolonged drug delivery. It defines ocular inserts and describes different types including soluble, insoluble, and erodible inserts. Applications include treatments for glaucoma, infections, and inflammation. Advantages are prolonged contact time and drug release, while disadvantages include potential loss or irritation. The document outlines manufacturing methods and innovations in ocular insert technologies and drug delivery to the eye.
Preformulation studies characterize the physical and chemical properties of drug molecules to develop safe, effective, and stable dosage forms. The goals are to develop formulations that are stable, safe, and effective. Major areas of study include physical characterization of properties like crystallinity and polymorphism, hygroscopicity, particle size, and powder flow. Solubility is analyzed through measurements of ionization, partition coefficient, aqueous solubility, and pH-solubility profiles. Stability is analyzed through studies of photolytic stability, stability to oxidation, and drug-excipient compatibility.
2 Aspects of compatibility tests are:
Identification of compatible excipients for a formulation.
Identification of stable storage conditions
2 Types:
Solid state reactions: much slower and difficult to interpret.
Liquid state reactions: easier to detect
According to Stability Guidelines by FDA following conditions should be evaluated for solutions or suspensions
1. Acidic or alkaline pH.
2. Presence of added substances
3. High oxygen and nitrogen atmospheres.
4. Effect of stress testing conditions.
This document discusses various aspects of drug release and dissolution. It begins by defining the five types of dosage forms that can be characterized by in vitro release, including solid oral dosage forms. It then discusses key concepts like drug products, drug substances, drug release mechanisms for different release types (immediate, delayed, extended), and modified-release dosage forms. The document also provides the definitions and differences between dissolution-controlled systems, diffusion-controlled systems, and combined dissolution-diffusion systems. It introduces mathematical models for drug dissolution like the Noyes-Whitney equation and Hixson-Crowell cube root equation. Finally, it discusses factors that affect drug dissolution and release rates.
Excipients are inactive substances formulated with active pharmaceutical ingredients to create drug products. They serve important purposes like bulking up formulations, ensuring consistent drug release and stability, and determining properties of the final dosage form like tablet size and dissolution rate. Common excipients include diluents, binders, disintegrants, lubricants, and glidants. Diluents increase volume and include substances like lactose, starch and calcium phosphate. Binders promote adhesion while disintegrants facilitate breaking of tablets. Lubricants prevent adhesion during compression and glidants promote powder flow. Proper excipient selection is crucial for an efficacious and robust drug product.
This document provides an overview of inhalation aerosols, including the propellants used, packaging, and filling techniques. It discusses the main components of aerosols like propellants, containers, valves, and actuators. The two main types of propellants are liquefied gas propellants and compressed gas propellants. It also summarizes the advantages and disadvantages of aerosols as well as the pressure filling and cold filling methods used to manufacture pharmaceutical aerosols.
Evaluation of transdermal drug delivery systemSagar Savale
This document discusses the evaluation of transdermal drug delivery systems. Key aspects that are evaluated include physicochemical properties, adhesive properties, in vitro studies, in vivo studies, stability studies, and toxicological studies. These evaluations are important to ensure consistency between batches in terms of quality, performance, reproducibility and stability, and to predict factors that may influence drug delivery.
Gastro retentive drug delivery system (GRDDS)Shweta Nehate
This document discusses gastro-retentive drug delivery systems (GRDDS), which aim to prolong the gastric residence time of drugs and target drug release in the upper gastrointestinal tract. It describes the physiology of the gastrointestinal tract and potential drug candidates for GRDDS. Various approaches for GRDDS are covered, including floating, high density, bioadhesive, swelling, and superporous hydrogel systems. Evaluation parameters, applications, marketed formulations, and conclusions about GRDDS are also summarized.
1. Capsules are solid dosage forms that enclose one or more active ingredients in a soluble gelatin shell for oral administration. Hard capsules use gelatin and contain dry powders, while soft capsules contain oils or liquids dissolved in oils.
2. Capsules are manufactured through rotary die or reciprocating die processes that form, fill, seal and cut the gelatin shells. The gelatin used is type A or B derived from animal collagen.
3. Finished capsules are tested for attributes like size, shape, weight uniformity, content uniformity, and dissolution. Soft gelatin capsules provide benefits like protecting unstable ingredients and increasing bioavailability but have certain material limitations.
Anatomy of eye and adrena, absorption of drug in the eye, classification of ophthalmic
products, safety consideration of ophthalmic products, formulation, vehicles and additives,
manufacturing consideration, environment, manufacturing techniques, quality control of
ophthalmic products, packaging of ophthalmic products.
The phenomenon of complex formation of drug with protein is called as Protein drug binding. The proteins are particularly responsible for such an interaction. A drug can interact with several tissue components.
ALZET osmotic pumps are implantable devices that continuously deliver solutions over a set duration at a constant rate. They offer a simple alternative to repetitive injections by providing around-the-clock exposure to test agents without needing frequent animal handling. ALZET pumps work through osmosis, using no batteries or electronics. They have various sizes to deliver agents from 1 day to 6 weeks at controlled rates. Common applications include delivering drugs, hormones, and other compounds in animal research.
This document provides an overview of microencapsulation techniques with a focus on coacervation phase separation. It defines coacervation as the partial desolvation of a homogeneous polymer solution into a polymer-rich phase and poor polymer phase. The key steps of coacervation formation are the formation of three immiscible chemical phases, deposition of the coating, and rigidization of the coating. Various techniques used for coacervation include changes in temperature, addition of incompatible polymers, addition of non-solvents, addition of salts, and polymer-polymer interactions. Modified coacervation techniques discussed include aqueous phase separation, organic phase separation, solvent evaporation, encapsulation by polyelectrolyte multilayer, hydrogel micro
Polymers Used in Pharmaceutical SciencesOyshe Ahmed
INTRODUCTION
CLASSIFICATION AND CHARACTERISTICS OF POLYMERS
MECHANISM OF DRUG RELEASE FROM POLYMER
BIO DEGRADATION OF POLYMERS
SYNTHESIS OF POLYMERS
POLYMERS USED IN FORMULATION OF DIFFERENT DRUG DELIVERY SYSTEM.
APPLICATION OF POLYMERS
The document discusses thixotropy, which is defined as the reversible transformation of a semi-solid material from a solid state to a liquid state and back again due to applied stress over time. Examples of thixotropic materials include ketchup, paints, and yogurt. A key characteristic of thixotropic materials is their hysteresis loop, which is formed on a rheogram by the upcurve and downcurve of viscosity with increasing and decreasing shear rates. The area of the hysteresis loop can be used to measure the degree of thixotropic breakdown. Thixotropy is a desirable property for liquid pharmaceuticals as it allows the material to have a high consistency at rest but flow easily upon shaking before reg
This document summarizes ocular drug delivery systems. It discusses barriers to drug permeation through the eye such as anatomical barriers like the cornea and physiological barriers like tear turnover. It also discusses strategies to overcome these barriers, including using viscosity enhancers to prolong precorneal residence time, penetration enhancers to increase corneal permeability, and various drug delivery vehicles like ointments, gels, liposomes, nanoparticles, microemulsions, and in-situ forming gels that can enhance ocular absorption and bioavailability. The ideal ocular delivery system maximizes precorneal residence time and drug absorption while minimizing systemic exposure and side effects.
This document discusses drug interactions at plasma and tissue binding sites. It describes the mechanisms of protein drug binding, including reversible and irreversible binding via hydrogen bonds, hydrophobic bonds, ionic bonds, and Vander Waal's forces. It explains how drugs can bind to blood components like plasma proteins, albumin, alpha-1-acid glycoprotein, lipoproteins, globulins, and blood cells. It also discusses how drugs can bind to extravascular tissues in organs like the liver, kidneys, lungs, and muscles. The significance of protein and tissue binding on drug absorption, distribution, elimination, therapy and drug targeting is explained.
The document describes different types of tablets classified by method of administration and mechanism of action. Tablets can be ingested orally and include standard, enteric coated, chewable and effervescent varieties. Others are used in the oral cavity as buccal, sublingual or lozenges. Implantation and vaginal tablets are administered by other routes. Tablet types aim to protect drugs, modify release timing, or produce solutions for various therapeutic effects.
This document compares different methods for comparing dissolution profiles of drug products. It defines dissolution profile comparison and its objectives such as developing bioequivalent products and in vitro-in vivo correlations. Graphical, statistical, model-dependent and model-independent methods are described. The most common model-independent method is the f2 similarity factor test recommended by the FDA, which provides a single value to determine if two dissolution profiles are similar based on the percent dissolved over time. Proper selection of time points and criteria for coefficient of variation are important for f2 testing.
ocular barriers and methods to overcome barriersTarun Gollapudi
This document summarizes barriers to ocular drug delivery and methods to overcome them. The major barriers include ocular surface barriers like the cornea, ocular wall barriers like the sclera, retinal barriers, the vitreous body, lachrymal fluid, and properties of the drug itself like solubility and molecular weight. Methods to enhance delivery include microneedles, ultrasound, iontophoresis, periocular routes, and intravitreal injections. Various ophthalmic formulations are also discussed like eye drops, gels, ointments, and inserts that utilize approaches like prodrugs, penetration enhancers, and nanoparticle carriers to improve ocular bioavailability.
This document discusses ophthalmic products and drug delivery to the eye. It provides information on general requirements for ocular formulations including safety, toxicity, and preservation. It describes the anatomy and physiology of the eye and barriers to drug absorption such as tear drainage and corneal permeability. The document outlines various approaches for ocular drug delivery including in-situ gels, liposomes, nanoparticles, inserts and implants to prolong drug residence in the eye.
The document provides an overview of ophthalmic products and drug delivery systems for the eye. It discusses general requirements for ocular formulations including safety, toxicity, preservation and barriers to drug absorption in the eye. It also describes various conventional and novel ocular drug delivery approaches such as in-situ gels, liposomes, nanoparticles, inserts and implantable systems. The anatomy and physiology of the eye is reviewed along with factors affecting drug availability after ocular administration.
The document discusses ocular drug delivery systems. It begins with an agenda that outlines the objectives and topics to be covered, including the anatomy and physiology of the eye, factors affecting intraocular bioavailability, and various approaches and classifications of ocular drug delivery systems. The document then provides details on the anatomy of the eye, mechanisms of ocular absorption, factors that influence drug availability in the eye, and different approaches to improve ocular bioavailability such as using viscosity enhancers, penetration enhancers, prodrugs, and mucoadhesives. It also describes various types of ocular delivery systems including solutions, suspensions, gels, ointments, inserts, and intraocular implants and injections.
The document discusses ocular drug delivery systems. It begins by outlining the objectives of studying these systems and reviewing various approaches to improve drug absorption through the eye. It then describes commonly used ophthalmic dosage forms like solutions, suspensions, and ointments. However, these preparations are rapidly drained from the eye via tear flow and drainage. Therefore, newer sustained release forms were developed like gels, inserts, and implants to prolong the drug's residence time in the eye. The document summarizes the anatomy of the eye, factors affecting ocular drug absorption, and various strategies to enhance the bioavailability and efficacy of ophthalmic formulations.
it is a complete overview on ophthalmic dosage form. beginning from anatomy and physiology of eye with drug absorption mechanism including all factors to formulation considerations and evaluation of the products i.e. eye drops and eye ointment & the evaluation tests. it will help you make the concepts clear about ophthalmic drug deliveries.
This document provides an overview of ocular drug delivery systems (ODDS). It discusses the advantages and disadvantages of ODDS, ideal characteristics, formulations, classifications like Ocuserts, barriers to ocular absorption, evaluation methods, and reasons for poor bioavailability. Ocuserts are described as elliptical drug delivery devices that continuously release drugs like pilocarpine for 7 days when placed in the eye. Barriers to absorption include the cornea, conjunctiva, sclera, aqueous humor, and retinal barriers. Evaluation methods covered include thickness, drug content, weight variation tests, moisture absorption tests, in vitro diffusion tests, in vivo studies in animals, and accelerated stability studies.
OCCULAR DRUG DELIVERY SYSTEM-pawan -.pptPawanDhamala1
This document discusses various ophthalmic drug delivery systems. It begins with an overview of traditional ophthalmic preparations like solutions, suspensions, ointments and their limitations. It then covers advanced controlled release systems including inserts, collagen shields, and vesicular systems. Specific examples like Pilocarpine Ocusert are described. The document discusses evaluation methods for ocular drug delivery systems and concludes with future trends, which may involve use of carbon nanotubes.
This document discusses ocular drug delivery systems. It begins by introducing different methods of administering drugs to the eye and the goals of an ideal ocular drug delivery system. It then describes the barriers to effective ocular drug delivery, including anatomical barriers like the cornea and physiological barriers like tear drainage. Novel drug delivery systems aim to overcome these barriers and provide sustained drug release through methods like inserts, nanoparticles, and liposomes. The document concludes by stating that advances in ocular drug delivery research aim to develop safer and more effective formulations.
This document discusses ophthalmic drug delivery systems such as contact lenses and ocular inserts. It provides information on the anatomy of the human eye, barriers to ocular absorption, and factors affecting intraocular bioavailability. Various ophthalmic preparations are classified and described, including conventional dosage forms as well as advanced drug delivery systems like nanoparticles, liposomes, and implants. Contact lenses are discussed in detail, outlining the different types and materials used as well as care solutions. Ocular inserts are introduced as controlled drug delivery devices that prolong the contact time between drugs and ocular tissues.
This document discusses various advanced ophthalmic drug delivery systems. It begins by defining ophthalmic dosage forms and noting limitations of conventional forms like rapid drainage. It then introduces newer forms like liposomes, nanoparticles, mucoadhesives and ocular inserts that provide sustained release and site targeting. It proceeds to describe specific examples and advantages of various advanced forms including mucoadhesives, ocular inserts, contact lenses and nanoparticles.
The document discusses ocular drug delivery systems. It describes the anatomy and physiology of the eye and factors that influence drug absorption through the cornea. Various ocular drug delivery formulations are discussed including solutions, suspensions, emulsions, ointments, polymeric solutions, and particulate/vesicular systems. Recent advances include bioadhesive systems, collagen shields, pseudolatices, and penetration enhancers. Ocular inserts provide sustained drug release and increased bioavailability. Evaluation methods for these systems include in vitro drug release and in vivo studies in animals.
The document discusses ocular drug delivery systems (ODDS). It begins with an introduction to ODDS and describes the anatomy and physiology of the eye. It then discusses common eye diseases, factors affecting ocular drug absorption, and barriers to intraocular drug delivery. Methods to overcome these barriers through novel ocular formulations are presented, including ocular inserts, which can enhance drug residence time and bioavailability. Examples of both non-erodible and erodible ocular insert systems are provided. The document concludes with a discussion of how novel formulations can improve ocular drug delivery.
INTRODUCTION :
Ocular administration of drug is primarily associated with the need to treat ophthalmic diseases.
Eye is the most easily accessible site for topical administration of a medication.
Ideal ophthalmic drug delivery must be able to sustain the drug release and to remain in the vicinity of front of the eye for prolong period of time.
The bioavailability of ophthalmic drugs is very poor due to efficient protective mechanisms of the eye.
Blinking, reflex lachrymation, and drainage rapidly remove drugs, from the surface of the eye.
To overcome these, two approaches can be followed.
The first involves using alternate delivery routes to conventional ones allowing for more direct access to intended target sites.
Second approach involves development of novel drug delivery systems providing better permeability, treatability and controlled release at target site.
Combination of both these approaches are being utilized and optimized in order to achieve optimal therapy with minimal adverse effects.
This document discusses ocular drug delivery systems. It begins by introducing the need for ocular drug delivery to treat eye diseases and the benefits of topical administration. It then covers conventional dosage forms like solutions and gels as well as advanced controlled release systems like inserts, contact lenses, and implants. Vesicular systems like liposomes and niosomes are described as ways to encapsulate both hydrophilic and hydrophobic drugs and provide sustained release. The ideal properties of ocular delivery systems are prolonged residence at the eye, sustained drug release, and patient comfort. Barriers to drug delivery via the eye are also summarized.
This document discusses ocular drug delivery systems. It begins by defining an ocular drug delivery system as a novel approach where drugs are instilled in the eye's cul-de-sac cavity. It then describes the anatomy and barriers of the eye, including the anterior and posterior segments, tear film, and blood-ocular barriers. Various ocular drug delivery formulations are discussed such as inserts, vesicles, and controlled release systems. Barriers to ocular drug delivery like drainage, absorption, and permeability are outlined along with methods to overcome them like intravitreal injections. Ideal characteristics and factors affecting bioavailability of ocular delivery systems are also summarized.
This document presents information on parenteral depot systems for long acting drug formulations. It discusses various approaches for controlled drug release including the use of viscous vehicles, polymeric microspheres, and drug derivatives. Common polymers used in depots are described as well as desirable characteristics. The main types of depot formulations are discussed - dissolution controlled, adsorption, encapsulation, and esterification. Examples of specific long acting preparations are provided for antibiotics, insulin, vitamin B12, and contraceptives. Evaluation methods and the development of depots are outlined.
Ophthalmic drug delivery systems aim to enhance drug bioavailability in the eye. Topical eye drops are commonly used but have poor bioavailability due to barriers like tear turnover and drainage. Various approaches can improve ocular drug delivery, such as using viscosity enhancing polymers to prolong precorneal residence time, penetration enhancers to increase corneal permeability, and particulate systems like liposomes, niosomes and nanoparticles that can encapsulate drugs. In situ forming gels are also used, which are liquid on instillation and form a gel in the eye to increase retention time. Overall, optimizing ophthalmic formulations can help overcome barriers to improve drug absorption and efficacy.
The document summarizes ocular drug delivery systems. It describes how drugs are administered topically to the eye and discusses the barriers to drug absorption, including drainage via the lacrimal system, barriers posed by the cornea and conjunctiva, and blood-ocular barriers. The ideal characteristics of ocular drug delivery systems are outlined as well as advantages such as increased dosing accuracy and sustained drug delivery.
The document provides information on liquid oral dosage forms. It discusses monophasic and biphasic liquid dosage forms, as well as the vehicles, excipients, and formulation considerations involved in producing liquid oral medications. Specifically, it covers emulsions, suspensions, syrups, and elixirs - the main types of liquid oral dosage forms. It also addresses the advantages and disadvantages of liquid dosage forms, as well as best practices for manufacturing, evaluating, and packaging these drug formulations.
Tablets: a.Introduction, ideal characteristics of tablets, Classification of tablets. Excipients, Formulation of tablets, granulation methods, compression and processing problems.
Enzymes involved in rDNA technology.pptxPoonam Patil
This document discusses the key enzymes involved in recombinant DNA technology. It describes how restriction enzymes cut DNA at specific recognition sites, and DNA ligases join cut DNA fragments back together. The document outlines the process of recombinant DNA technology, including generating DNA fragments, inserting them into cloning vectors, introducing the vectors into host cells, and expressing the gene of interest. It provides details on various restriction enzymes and DNA-modifying enzymes used in genetic engineering applications.
FLUID FLOW
A fluid is a substance that continually deforms (flows) under an applied shear stress. Fluids are a subset of the phases of matter and include liquids, gases.
“Fluid flow may be defined as the flow of substances that do not permanently resist distortion”
The subject of fluid flow can be divided into-
fluid statics
fluid dynamics
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
How to Make a Field Mandatory in Odoo 17Celine George
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
বাংলাদেশের অর্থনৈতিক সমীক্ষা ২০২৪ [Bangladesh Economic Review 2024 Bangla.pdf] কম্পিউটার , ট্যাব ও স্মার্ট ফোন ভার্সন সহ সম্পূর্ণ বাংলা ই-বুক বা pdf বই " সুচিপত্র ...বুকমার্ক মেনু 🔖 ও হাইপার লিংক মেনু 📝👆 যুক্ত ..
আমাদের সবার জন্য খুব খুব গুরুত্বপূর্ণ একটি বই ..বিসিএস, ব্যাংক, ইউনিভার্সিটি ভর্তি ও যে কোন প্রতিযোগিতা মূলক পরীক্ষার জন্য এর খুব ইম্পরট্যান্ট একটি বিষয় ...তাছাড়া বাংলাদেশের সাম্প্রতিক যে কোন ডাটা বা তথ্য এই বইতে পাবেন ...
তাই একজন নাগরিক হিসাবে এই তথ্য গুলো আপনার জানা প্রয়োজন ...।
বিসিএস ও ব্যাংক এর লিখিত পরীক্ষা ...+এছাড়া মাধ্যমিক ও উচ্চমাধ্যমিকের স্টুডেন্টদের জন্য অনেক কাজে আসবে ...
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UPRAHUL
This Dissertation explores the particular circumstances of Mirzapur, a region located in the
core of India. Mirzapur, with its varied terrains and abundant biodiversity, offers an optimal
environment for investigating the changes in vegetation cover dynamics. Our study utilizes
advanced technologies such as GIS (Geographic Information Systems) and Remote sensing to
analyze the transformations that have taken place over the course of a decade.
The complex relationship between human activities and the environment has been the focus
of extensive research and worry. As the global community grapples with swift urbanization,
population expansion, and economic progress, the effects on natural ecosystems are becoming
more evident. A crucial element of this impact is the alteration of vegetation cover, which plays a
significant role in maintaining the ecological equilibrium of our planet.Land serves as the foundation for all human activities and provides the necessary materials for
these activities. As the most crucial natural resource, its utilization by humans results in different
'Land uses,' which are determined by both human activities and the physical characteristics of the
land.
The utilization of land is impacted by human needs and environmental factors. In countries
like India, rapid population growth and the emphasis on extensive resource exploitation can lead
to significant land degradation, adversely affecting the region's land cover.
Therefore, human intervention has significantly influenced land use patterns over many
centuries, evolving its structure over time and space. In the present era, these changes have
accelerated due to factors such as agriculture and urbanization. Information regarding land use and
cover is essential for various planning and management tasks related to the Earth's surface,
providing crucial environmental data for scientific, resource management, policy purposes, and
diverse human activities.
Accurate understanding of land use and cover is imperative for the development planning
of any area. Consequently, a wide range of professionals, including earth system scientists, land
and water managers, and urban planners, are interested in obtaining data on land use and cover
changes, conversion trends, and other related patterns. The spatial dimensions of land use and
cover support policymakers and scientists in making well-informed decisions, as alterations in
these patterns indicate shifts in economic and social conditions. Monitoring such changes with the
help of Advanced technologies like Remote Sensing and Geographic Information Systems is
crucial for coordinated efforts across different administrative levels. Advanced technologies like
Remote Sensing and Geographic Information Systems
9
Changes in vegetation cover refer to variations in the distribution, composition, and overall
structure of plant communities across different temporal and spatial scales. These changes can
occur natural.
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
The simplified electron and muon model, Oscillating Spacetime: The Foundation...RitikBhardwaj56
Discover the Simplified Electron and Muon Model: A New Wave-Based Approach to Understanding Particles delves into a groundbreaking theory that presents electrons and muons as rotating soliton waves within oscillating spacetime. Geared towards students, researchers, and science buffs, this book breaks down complex ideas into simple explanations. It covers topics such as electron waves, temporal dynamics, and the implications of this model on particle physics. With clear illustrations and easy-to-follow explanations, readers will gain a new outlook on the universe's fundamental nature.
Main Java[All of the Base Concepts}.docxadhitya5119
This is part 1 of my Java Learning Journey. This Contains Custom methods, classes, constructors, packages, multithreading , try- catch block, finally block and more.
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar Kanvaria
Walmart Business+ and Spark Good for Nonprofits.pdfTechSoup
"Learn about all the ways Walmart supports nonprofit organizations.
You will hear from Liz Willett, the Head of Nonprofits, and hear about what Walmart is doing to help nonprofits, including Walmart Business and Spark Good. Walmart Business+ is a new offer for nonprofits that offers discounts and also streamlines nonprofits order and expense tracking, saving time and money.
The webinar may also give some examples on how nonprofits can best leverage Walmart Business+.
The event will cover the following::
Walmart Business + (https://business.walmart.com/plus) is a new shopping experience for nonprofits, schools, and local business customers that connects an exclusive online shopping experience to stores. Benefits include free delivery and shipping, a 'Spend Analytics” feature, special discounts, deals and tax-exempt shopping.
Special TechSoup offer for a free 180 days membership, and up to $150 in discounts on eligible orders.
Spark Good (walmart.com/sparkgood) is a charitable platform that enables nonprofits to receive donations directly from customers and associates.
Answers about how you can do more with Walmart!"
2. Ophthalmic Vs Ocular
❑ They are specialized & Conventional dosage
forms designed to be instilled onto the external
surface of the eye (topical), administered inside
(intraocular) or adjacent (periocular) to the eye
or used in conjunction with an ophthalmic
device.
● The most commonly employed ophthalmic
dosage forms are solutions, suspensions, and
ointments.
● These preparations when instilled into the eye
are rapidly drained away from the ocular cavity
due to tear flow and lacrimal nasal drainage.
❖ The newest dosage forms for ophthalmic drug
delivery are called as OCULAR DDS: gels, gel-
forming solutions, ocular inserts , intravitreal
injections and implants.
3. Drugs used in the eye:
● Miotics (Contraction of pupil) e.g. pilocarpine Hcl
● Mydriatics (Dilation of pupil) e.g. atropine
● Cycloplegics (paralyzes the ciliary body) e.g. atropine
● Anti-inflammatories e.g. corticosteroids
● Anti-infectives (antibiotics, antivirals and antibacterials)
● Anti-glucoma drugs (reduce the intra-ocular pressure)
e.g. pilocarpine Hcl
● Surgical adjuncts e.g. irrigating solutions
● Diagnostic drugs e.g. sodiumfluorescein
● Anesthetics e.g. tetracaine
4. Need of ocular drug delivery
● These Novel devices and/or formulations may help to
surpass ocular barrier and associated side effects
with conventional topical drops.
● It provides prolong drug retention thus better
absorption and consequently improved bioavailability.
● Helps to avoid pre-corneal elimination.
● Patient compliance is facilitated.
12. ● limited volume of administration (30 μL);
● fast clearance from ocular surface;
● Metabolism of the active by tear enzymes;
● nonproductive uptake into systemic circulation via highly
vascularized conjunctiva, choroid, uveal tract and inner
retina
● anterior membrane barriers (cornea, conjunctiva, and
sclera);
● aqueous humor outflow;
● long diffusional path ; and
● acellular nature of the vitreous, which may negatively
impact the pharmacokinetics and distribution of topically
applied drugs.
Barriers: Ocular DDS
18. Barriers for Ocular Drug Absorption
Depending on the route of administration:
1. Topical Precorneal factors
Solution drainage, Blinking, Tear dilution, Tear turnover, Induced lacrimation,
Conjuctival absorption
2. Physical barriers
Cornea
Sclera
Conjuctiva
3. Oral
4. Periocular and intravitreal
5. Parentetal
Blood aqueous barrier
Blood retinal barrier
19. Barriers for Ocular Drug Absorption –
Topical Route
Mostly in the form of eye drops
Employed to treat anterior segment diseases
Site of action is usually different layers of the cornea,
conjunctiva, sclera, iris and ciliary body.
Precorneal factors:
• Solution drainage, blinking, tear film, tear turn over, and induced
lacrimation
• Human tear volume is estimated to be 7 μl
• Mucin present in the tear film plays a protective role by forming a
hydrophilic layer that moves over the glycocalyx of the ocular
surface and clears debris and pathogens
• Contact time with the absorptive membranes is lower
• Less than 5% of the applied dose reaches the intraocular tissues
20.
21. Mechanical barriers for topical drug
absorption
Cornea
Limits the entry of exogenous substances into the eye and protects the ocular
tissues
Divided into the epithelium, stroma, and endothelium
The corneal epithelium is lipoidal in nature
Offers resistance for permeation of topically administered hydrophilic drugs
Corneal epithelium…
Corneal epithelial cells are joined to one another by desmosomes
Tight junctional complexes retards paracellular drug permeation from the tear film
into intercellular spaces of the epithelium as well as inner layers of the cornea
Layers of the Cornea Stroma
Comprises 90% of the corneal thickness
Highly hydrated structure
Barrier to permeation of lipophilic drug molecules
Endothelium
Endothelial junctions are leaky - facilitate the passage of macromolecules between
the aqueous humor and stroma
Drugs should have an amphipathic nature in order to permeate through these layers
22. Sclera
Consists of collagen fibers and proteoglycans embedded in an extracellular
matrix
Permeability - comparable to that of the corneal stroma
Positively charged molecules exhibit poor permeability presumably due to
their binding to the negatively charged proteoglycan matrix
Permeability of drug molecules across the sclera is inversely proportional
to the molecular radius
23.
24. Barriers for Ocular Drug Absorption
– Parenteral Route
Anterior segment: blood–aqueous barrier
Posterior segment: blood–retinal barrier
25. Blood–aqueous barrier
Tight junctional complexes and prevent the entry of
solutes into the intraocular environment such as the
aqueous humor
Blood–retinal barrier
Restricts the entry of the therapeutic agents from blood
into the posterior segment.
Regulates drug permeation from blood to the retina
36. ● “Smart” hydrogels, or stimuli-sensitive hydrogels, are very
different from inert hydrogels in that they can “sense”
changes in environmental properties such as pH and
temperature and respond by increasing or decreasing their
degree of swelling.
● The stimuli that induce various responses of the hydrogels
systems include physical (temperature) or chemical (pH,
ions) ones.
● There are many mechanisms have been employed to cause
reversible sol-gel phase transition by different stimuli.
STIMULI-SENSITIVE HYDROGELS
37. STIMULI-SENSITIVE HYDROGELS
● physiological environmental conditions of human body: The
stimuli that induce various responses of the hydrogel
● systems include-
● 1. Physical stimuli like: Change in temperature, electric
fields, light, pressure, sound, and magnetic fields.
● 2. Chemical stimuli like: Change in pH and ion activation
from biological fluid.
● 3. Biological/biochemical (bimolecular) stimuli like:
Change in glucose level
● In ophthalmic drug delivery three types of stimuli-sensitive
hydrogels - temperature sensitive, pH sensitive, and
● ion-sensitive hydrogels are mainly used.
39. Temperature-sensitive hydrogels
● Temperature-sensitive hydrogels are able to swell or de-swell as a result
of changing in the temperature of the surrounding fluid. For
convenience, temperature-sensitive hydrogels are classified into
negatively thermosensitive, positively thermosensitive, and
thermally reversible gels.
● Negative temperature-sensitive hydrogels have a lower critical
solution temperature (LCST) and contract upon heating above the
LCST. Copolymers of (Nisopropylacrylamide) (PNIAAm) are usually
used for negative temperature release. Hydrogels show an on off drug
release with on at a low temperature and off at high temperature
allowing pulsatile drug release. LCST systems are mainly relevant for
controlled release of drugs, and of proteins in particular.
Thermosensitive polymers may be fixed on liposome membranes; in
that case liposomes exhibit control of their content release.
40. ● Positive temperature-sensitive hydrogel has an
upper critical solution temperature (UCST), such
hydrogel contracts upon cooling below the UCST.
Polymer networks of poly (acrylic acid) (PAA)
and polyacrylamide (PAAm) or poly
(acrylamide-co-butyl methacrylate) have
positive temperature dependence of swelling.
Temperature-sensitive hydrogels
41. ● The most commonly used thermoreversible gels are these prepared from poly
(ethylene oxide)-b-poly (propylene oxide)-b-poly (ethylene oxide) (Pluronics
, Tetronics , poloxamer).
● Polymer solution is a free-flowing liquid at ambient temperature and gels at
body temperature, such a system would be easy to administer into desired
body cavity. Depending on the ratio and the distribution along the chain of
the hydrophobic and hydrophilic subunits, several molecular weights are
available, leading to different gelation properties Pluronic F127, which
gives colorless and transparent gels, is the most commonly used in
pharmaceutical technology.
● At concentrations of 20% w/v and higher aqueous solutions of Poloxamer-
407 remain as a liquid at low temperatures [<15°C] and yield a highly
viscous semisolid gel upon instillation into the cul-de-sac. At low
temperatures, the Poloxamer forms micellar subunits in solution, and
swelling gives rise to large micellar subunits and the creation of cross-linked
networks. The result of this phenomenon is a sharp increase in viscosity
upon heating.
Temperature-sensitive hydrogels
42. ● Three principal mechanisms have been proposed to explain the
liquid-gel phase transition after an increase in temperature,
including:
● 1. Gradual desolvation of the polymer,
● 2. Increased micellar aggregation, and
● 3. The increased entanglement of the polymeric network.
● Despite all the promising results obtained with thermo
reversible gels, there remains an important drawback
associated with their use; the risk of gelation before
administration by increase in ambient temperature during
packing or storage.
Temperature-sensitive hydrogels
43. pH-sensitive hydrogels
● These hydrogels respond to changes in pH of the external
environment. These gels have ionic groups (which are
readily ionizable side groups) attached to impart peculiar
characteristics. Some of the pH sensitive polymers used in
hydrogels’ preparations are
● polymethyl methacrylate (PMMA),
● polyacrylamide (PAAm),
● polyacrylic acid (PAA),
● poly dimethylaminoethylmethacrylate (PDEAEMA)
● polyethylene glycol.
44. ● These polymers though in nature are hydrophobic but swells in
water depending upon the pH prevalent in the external
environment. Any change in pH of the biological environment
causes changes in the swelling behavior,
● for example, the hydrogel of caffeine is prepared with polymer
PDEAEMA at pH below 6.6. As the polymer shows high
swellability but when pH changes to higher side, the polymer
showed shrinkage leading to drug release.
● The other pH-sensitive hydrogels are copolymer of PMMA and
polyhydroxyethyl methyl acrylate (PHEMA), which are anionic
copolymers, swell high in neutral or high pH but do not swell in
acidic medium. It was also observed that pH and ionic strength
determines kinetics of swelling of PHEMA and guar gum.
pH-sensitive hydrogels
45. ● Cellulose acetate phthalate (CAP) latex, cross linked
acrylic, and derivatives such as carbomer are used.
Cellulose acetate derivatives are the only polymer known to
have a buffer capacity that is low enough to gel effectively
in the cul-de-sac of the eye. The pH change of about 2.8
units after instillation of the native formulation (pH 4.4) into
the tear film leads to an almost instantaneous transformation
of the highly fluid latex into viscous gel.
● But the low pH of the preparation can elicit discomfort in
some patients. The poly acrylic acid and its lightly cross-
linked commercial forms (Polycarbophil and Carbopol)
exhibit the strongest muco-adhesion.
pH-sensitive hydrogels
46. ● Ion-sensitive polymers belong to the mainly used in situ
gelling materials for ocular drug delivery. Gelling of the
instilled solution is also triggered by change in ionic
strength. It is assumed that the rate at which electrolytes
from the tear fluid is absorbed by the polymer will depend
on the osmotic gradient across the surface of the gel.
● It is therefore likely that the osmolality of the solution might
have an influence on the rate of the sol-gel transition
occurring in the eye. One example is Gelrite, an anionic
extra cellular polysaccharide, low acetyl Gellan gum
secreted by pseudomonas elodea. Gelrite formulations in
aqueous solutions form a clear gel in the presence of the
mono or divalent cations typically found in the tear fluids.
Ion-sensitive hydrogels
47. Ion-sensitive hydrogels
● The electrolyte of the tear fluid and especially Na+, Ca++, and Mg++
cations are particularly suited to initiate gelation of the polymer when
instilled as a liquid solution in to the cul-de-sac. Gelrite has been the most
widely studied and seems to be preferred compared to the pH sensitive or
temperature setting systems. The polymeric concentration is much lower
compared to previously described systems.
● Slightly viscous gellan gum solutions in low concentrations (<1%) show
markedly increase in apparent viscosity, when introduced into presence of a
physiological level of cations, without requiring more ions than 10–25% of
those in tear fluid.The precorneal contact times for drugs can thus be
extended up to 20-h. Gellan-containing formulations of pilocarpine HCl
allowed reduction of drug concentration from 2% to 0.5% obtaining the
same bioavailability.
48.
49.
50.
51. Ocular Insert
Non erodible inserts
The Ocusert therapeutic system is a flat, flexible, elliptical device
designed to be placed in the inferior cul-de-sac between the sclera
and the eyelid and to release Pilocarpine continuously at a steady
rate for 7 days
Ocusert:
52. The device consists of 3 layers…..
● Outer layer – ethylene vinyl acetate copolymer layer.
● Inner Core – Pilocarpine gelled with alginate main polymer.
● A retaining ring - of EVA impregnated with titanium dioxide
53. The ocuserts available in two forms.
● Pilo – 20 (20 microgram / hour)
● Pilo – 40 (40 microgram / hour)
Use: Chronic glaucoma
Advantages
● Increase in ocular residence.
● Drug release at slow and constant rate.
● Increased shelf life compare to aqueous solutions.
● Accurate dosing
● Improved compliance.
● Can administer with inflammed eye.
● Save time of healthcare professional.
● Eliminate systemic side effects.
● Improved patient compliance.
60. Erodible Inserts
The solid inserts absorb the aqueous tear fluid and gradually
erode or disintegrate
The drug is slowly leached from the hydrophilic matrix
They quickly lose their solid integrity and are squeezed out of
the eye with eye movement and blinking
Do not have to be removed at the end of their use
Three types
● LACRISERTS
● SODI
● MINIDISC
61. Mechanism of inserts: Soluble or Erodible
● In swelling-controlled devices, the active agent is
homogeneously dispersed in a glassy polymer. Since glassy
polymers are essentially drug-impermeable, no diffusion
through the dry matrix occurs. When the insert is placed in the
eye, water from the tear fluid begins to penetrate the matrix,
then swelling and consequently polymer chain relaxation and
drug diffusion take place. The dissolution of the matrix, which
follows the swelling process, depends on polymer structure:
linear amorphous polymers dissolve much faster than cross-
linked or partially crystalline polymers. Thus, some inserts, even
if classified as S, may remain in the eye as empty ‘ghosts’ after
releasing their drug content. Release from these devices
follows in general Fickian ‘square root of time’ kinetics; in some
instances, however, known as case II transport, zero order
kinetics have been observed.
62. ● In truly erodible or E-type devices, the rate of drug
release is controlled by a chemical or enzymatic
hydrolytic reaction that leads to polymer
solubilization, or degradation to smaller, water soluble
molecules.
● These polymers may undergo bulk or surface
hydrolysis. Zero order release kinetics can be
displayed by erodible inserts undergoing surface
hydrolysis, provided that the devices maintain a
constant surface geometry and that the drug is poorly
water soluble.
Mechanism of inserts: Soluble or Erodible
63. 1. LACRISERTS
● Sterile rod shaped device made up of hydroxy propyl cellulose
without any preservative
● For the treatment of dry eye syndromes
● It weighs 5 mg & measures 12.5 mm in diameter with a length of
3.5 mm
● It is inserted into the inferior fornix
65. 2. SODI (Soluble Ocular Drug Inserts)
● Soluble Ocular Drug Inserts
● Small oval wafer
● Made up of water soluble synthetic polymer
● Sterile thin film of oval shape
● Weighs 15-16 mg
● Introduced into the inferior cul-de-sac.
Composition- Acryl amide, vinyl pyrolidone, Ethylacrylate.
Use – glaucoma
66. ● The SODIs are the result of a vast collaborative effort between
eminent Russian chemists and ophthalmologists, and led
eventually (in 1976) to the development of a new soluble
copolymer of acrylamide, N-vinylpyrrolidone and ethyl acrylate
(ratio 0.25 : 0.25 : OS),
● SOD1 in the form of sterile thin films of oval shape (9 x 4.5 mm,
thickness 0.35 mm), weighing 15-16 mg, and color-coded for
different drugs.
● After introduction into the upper conjunctival sac, a SOD1
softens in 10-15 s, conforming to the shape of the eyeball. In the
next 10-15 min the film turns into a polymer clot, which gradually
dissolves within 1 h while releasing the drug. The sensation of
an ‘extraneous body’ in the eye disappears in 5-15 min.
2. SODI
67. ● This dosage form was originally developed for astronauts to
apply it in the state of weightlessness. Drug release from
SODIs does not show vehicle control, and produces a
prolonged-pulse entry of the drug. However, due to the
capacity of the ocular tissues to act as drug reservoirs, a
single SOD1 application has been reported to replace 4-12
drop instillations or 3-6 applications of ointment,
● Drug is released from SODI in a pulsational, uncontrolled
manner, and the dosage form ensures its prolonged effect.
● Active ingredients employed in the course of research on
SODI include neomycin, kanamycin, atropine, pilocarpine,
dexamethasone, sulfapyridine, and tetracaine.
2. SODI
68. ● Based on natural polymers, for example, collagen.
● Based on synthetic or semi-synthetic polymers.
● The therapeutic agent is absorbed by soaking the insert in a
solution containing the drug, and drying and rehydrating it before
use in the eye. The amount of drug contained will depend upon the
capacity of the binding agent, concentration of the drug solution into
which the insert is soaked, and the duration of soaking.
● The soluble ophthalmic inserts are easily processed by
conventional methods – slow evaporating extrusion, compression
or injection molding. The release of the drug takes place when
tears penetrate into the insert. This induces drug release by
diffusion and forms a layer of gel around the core of the insert. This
gelification causes further release of the drug, but it is still
controlled by diffusion. The release rate, J, is derived from Fick's
law, which yields the following expression
2. SODI
69. Advantages:
● Single SODI appliction: repaces 4-12 eye drops
instiation. Or 3-6 applications of ointments.
● Once a day treatment of Glaucoma.
● In 10-15 Sec softens; In 10-15 min turns in viscous
liquid; After 30-60 min becomes a polymeric solution.
API: Neomycin, kanamycin, atropine, pilocarpine,
dexamethasone, sulfapyridine, and tetracaine
2. SODI
70. 3.MINIDISC
Countered disc with a convex front and a concave back
surface in contact with eye ball.
Diameter – 4 to 5 mm
Composition
Soluble copolymers consisting of actylamide, N-vinyl
pyrrolidone and ethyl acetate
-Silicone based prepolymer-alpha-w-dis (4-
methacryloxy)-butyl poly di methyl siloxane. (M2DX)
M-Methyl acryloxy butyl functionalities.
D – Di methyl siloxane functionalities.
Pilocarpine, chloramphenicol
Drug release: upto 170hrs.
71.
72.
73. Contact lenses - Challenges
● Incorporation of sufficient amounts of the drug into the lens
matrix;
● sustaining the drug release for the desired time frame at a
controlled rate;
● Good optical clarity;
● Patient comfort during prolonged wear; and biocompatibility.
● Prolonged wear of contact lens is associated with risk of
infection such as microbial keratitis and dry eye syndrome.
● Wearing of contact lenses is contraindicated in various
inflammatory conditions of anterior segment such as anterior
uveitis, vernal conjunctivitis, microbial keratitis and dry eye
syndrome, limiting the applicability of this delivery system.
74. The routes of drug delivery by contact lens
● Drug- loded contact lenses are
worn on the cornea to achieve
topical administration for the
management of ocular diseases.
● As shown in Fig.2, a human tear
film contains approximately 6–7 μl
of fluid to form a thickness of 7–10
μm.
● When contact lenses are not worn,
the tear film covers the cornea,
however, after the insertion of a
contact lens the tear film is divided
into the PLTF and the POLTF.
75. ● The PLTF is located on the anterior side of the contact lens,
which has direct exposure to air, while the POLTF is located
between the cornea and the posterior segment of the contact
lens .
● Therapeutic agents in contact lenses are released into both the
PLTF and the POLTF. The drug released from the contact lens
into the POLTF can be subsequently delivered into the cornea or
radially diffuse outwards into the outer tears, and the periodic
lens motion can enhance the radial transport.
● The drug delivered into the cornea can reach the anterior
segment for the management of ocular diseases through the
corneal route. Reversely, drug released from the contact lens
into the PLTF is dominantly absorbed into the conjunctiva,
further entering the posterior segment and systemic circulation,
or drained by the canaliculus.
The routes of drug delivery by contact lens
76. The process of manufacturing contact lens
by different methods
● a. lathe-cut method; b. spin casting method; c. injection molding method.
● CL: Contact lens; HIGH THEM: High temperature.
78. Soaking in Drug Solutions
● The traditional method is to soak the preformed contact lens in drug
solution so that the drug is adsorbed into the polymeric lenses. Drug
loading is achieved be either being dissolved in the aqueous phase of the
contact lens, or being physically adsorbed on the polymer matrix.
● Due to the drug concentration difference between the soaking solution and
aqueous phase of contact lens, molecular diffusion is the main driving
force for drug delivery into contact lenses, and is subsequently also the
mechanism of drug release from the contact lens.
● Although soaking of preformed contact lenses in drug solution is an easy
way to incorporate the drug, this approach suffers from various limitations
including low drug loading and fast diffusion of the drug from the lenses.
● Drug upload and release by the soaking method is related to certain
factors such as drug concentration in the soaking solution, the molecular
weight of the drug, the lens thickness, the type and water content of the
lens.
79. Soaking in Drug Solutions
● Drugs with a low molecular weight, between 300 and 500 Da, are
released from the contact lens over a few minutes to a few hours . High
molecular weight drugs such as hyaluronic acid have difficulties
penetrating the aqueous channels of contact lens and only remain on
the surface
● Such presoaked lenses allow limited, slow release of the drug into the
post-lens lacrimal fluid. Soft contact lenses made from poly-
hydroxymethacrylate (pHEMA) hydrogels release the majority of their
drug content in one day.
81. Cyclodextrin-based contact lens
A. Copolymerization of acrylic/vinyl CDs derivatives
B. Grafting of CDs to preformed polymer networks
C. Directing cross-linking of CDs
82. ● Molecularly imprinted contact lenses exhibited a more prolonged drug release when
compared with lenses soaked in drug solution. Molecularly imprinted contact lenses
of ketotifen (diffusion coefficient: 5.57 ± 0.31 × 10 cm2 /s) showed a diffusion
coefficient that was nine-times lower than nonimprinted lenses (50.2 ± 4.8 × 10 cm2
/s).
Molecularly imprinted polymeric hydrogels
83. Conjugation of nanoparticles or drug
molecules to contact lens surface
● Another approach to prepare contact lens drug delivery systems is to immobilize the
drug or drug-loaded nanocarriers such as liposomes and nanoparticles on the
surface of commercial soft contact lenses.
● This can be achieved by surface functionalization of contact lenses to attach the
drug or nanocarriers. Surface immobilization of levofloxacin liposomes on
NeutrAvidin-coated Hioxifilcon-B contact lenses resulted in slower release than drug
soaked lenses.
● However, most of the drug (70%) was released within the first 5 h, with 30%
remaining drug release occurring over the next 6 days. Thus, the drawback of this
approach is the relatively rapid detachment or disintegration of liposomes in the
contact lenses.
● The lipid layer may also impede O2 and CO2 permeability.
84.
85.
86. ● Recent research from the
Massachusetts Eye & Ear
Infirmary (Needham, MA, USA)
demonstrated that near zeroorder,
4-week release of ciprofloxacin
and fluorescein is feasible from a
drug-polymer film (poly[lactide-co-
glycolide] [PLGA] 65:35) coated
with a hydrogel (pHEMA) contact
lens.
● In vitro release studies showed
that the drug release rate can be
reduced by using highmolecular-
weight polymers or increasing the
polymer-to-drug ratios.
Drug-polymer films integrated with contact
lenses
87. Liposome-loaded contact lenses
● In this method, drug-loded nanoparticles,
liposomes or surfactant are added to the
polymerizing medium of hydrogel matrix
followed by polymerization to form contact
lenses dispersed with drug carriers.
● The overall drug release can be regulated by
controlling the release of the drug from the
various carriers, followed by the lens matrix to
the post-lens tear film.
● Contact lenses created with dispersion of
lidocaine loaded liposomes or nano-particles
showed nonlinear release of drug for 7 days,
with an initial 15–20% burst release over the
first few hours followed by near zero-order
release for the remaining 7 days.
88. Scleral lens delivery systems
● The scleral lenses were first approved by the FDA in 1994 for the management of
ectasia and irregular astigmatism. Scleral lenses are large diameter lenses which
rest over the sclera, unlike the conventional contact lenses which rest on the cornea.
● These lenses are fitted to not touch the cornea and there is a space created
between the cornea and the lens. These lenses are inserted in the eyes after filling
with sterile isotonic fluid.
● A scleral lens rests on the sclera and creates a space over the cornea and limbus,
acting as a reservoir for tear fluid between the inner surface of the scleral lens and
the cornea to form an expanded tear film.
● This expanded tear film over the cornea acts as a liquid bandage in corneal surface
irregularities.
● The scleral lens allowed improved retention of topically applied drug on the corneal
surface in the expanded tear film, that is, the tear film or artificially introduced tears
retained between the corneal surface and the scleral lens.
● The drug may be added to the scleral lens, which acts as a reservoir for sustained
release of the drug, or administered externally as an eye drop, which is retained in
the expanded precorneal tear film.
● The topical delivery of Avastin for the treatment of corneal neovascularization using
scleral lens delivery system showed promising results in a clinical study with five
patients.
91. Non-biodegradable polymeric implants
● These implants can entrap drug either by dispersion throughout
a polymer matrix or storage inside a reservoir surrounded by a
release controlling non-biodegradable polymer membrane.
● Drug release from non-biodegradable matrix systems is
governed by diffusion and an initial burst is often observed.
● On the other hand, reservoir systems release the drug either
through permeable non-biodegradable membranes or ia a small
orifice in an impermeable membrane.
● Both of these systems have shown near zero order drug release
of effective concentrations over extended periods of time.
● Polyvinyl alcohol (PVA), ethylene vinyl acetate (EVA) and silicon
are the most commonly used non-biodegradable polymers for
ocular implants.
92. ● Silicon and EVA are hydrophobic in nature and are mainly used
as membranes with limited permeability in reservoir based
systems. On the other hand, PVA is more hydrophilic and
therefore permeable to a broader range of drugs. Often a
combination of PVA with either EVA or silicon is utilized to
optimize drug release from the implant.
● Vitrasert, approved by the FDA in 1996, is a non-biodegradable
implant containing 4.5 mgof ganciclovir for the treatment of CMV
retinitis. It contains the drug in form of a pellet coated with two
layers of nonbiodegradable polymers. The inner coating is PVA,
with the outer impermeable coating of EVA on three sides and
an additional PVA layer on the remaining side. Drug permeates
via the permeable PVA coated side at a rate of approximately 24
μg/day and the implant has shown clinical suppression of
disease symptoms over five to eight months.
Non-biodegradable polymeric implants
93. ● Vitrasert is sutured to the pars plana region of the sclera.
Common complications with the use of this implant include
endophthalmitis, cataract formation, intraocular pressure
increase and risk of retinal detachment.
● In general, non-biodegradable polymers are preferred for implant
fabrication to deliver therapeutics to the posterior segment as
they release the drug in a more controlled manner over
extended periods of time, while also offering easier removal in
case of adverse reactions. Fabrication of refillable non-
biodegradable implants might therefore be advantageous in
terms of patient compliance and overall treatment costs.
Non-biodegradable polymeric implants
94. Biodegradable polymeric implants
● These implants are made from biodegradable polymers entrapping the drug either throughout a
polymer matrix or in form of a reservoir with biodegradable polymer coating. From matrix
systems the drug is released through a combination of diffusion and polymer degradation.
● In reservoir based implants drug is mainly released through a pore in the otherwise impermeable
membrane with the biodegradable polymer coating degrading relatively slow compared to the
drug release out of the system. With matrix biodegradable systems, there is generally an initial
burst and then a fairly constant release rate over time, with a final burst observed in reservoir
systems. Drug release can vary depending on the surface area, rate of polymer degradation,
polymer swelling, molecular weight and nature of the drug molecule.
● Polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-co-glycolic acid) (PLGA),
polycaprolactones (PCL), polyanhydrides (PA) and polyortho esters (POE) are commonly used
biodegradable polymers for ophthalmic drug delivery, with PLGA being the most widely studied.
These polymers are all aliphatic esters which are degraded in the body by water and/or enzymes
with their degradation products being metabolized into CO2 and water.
95. ● Ozurdex, the first biodegradable intravitreal implant approved by the
FDA, is a cylindrical implant comprising dexamethasone dispersed in a
PLGA matrix based on the NOVADUR® technology (Allergan). It
contains 700 μg of dexamethasone and has proven to be clinically
effective for up to sixmonths in the treatment of diabetic macular edema
and non-infectious uveitis. It is injected into the vitreous via a 22-gauge
needle and exhibits fast drug release over the first twomonths due to
diffusion of the drug and degradation of the polymer after which solely
polymer degradation is responsible for the slower drug release over the
following four months.
96.
97. Stimuli-responsive implants
● Implants made from stimuli-responsive polymers exhibit abrupt
changes in structure, solubility, charge, volume and
hydrophobic– hydrophilic balance in response to physical or
chemical changes in the environment and can be utilized to tune
drug release rates.
98. Iontophoresis
● Iontophoresis is a noninvasive technique for ocular drug delivery, and therefore
avoids the complications of a surgical implantation or frequent and high dose of
intravitreal injections. The drug is applied with a weak direct current (DC) that drives
charged molecules across the sclera and into the choroid, retina, and vitreous. A
ground electrode of the opposite charge is placed elsewhere on the body to
complete the circuit.
● The drug serves as the conductor of the current through the tissue. In the rabbit
iontophoresis of DEX phosphate, DEX levels in the cornea after a single
transcorneal iontophoresis for 1 min (1 mA) were up to 30 fold higher compared to
those obtained after frequent eye-drops instillation.